Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2016 - 2025)

Enanta Pharmaceuticals' Cash & Equivalents history spans 14 years, with the latest figure at $37.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 55.62% year-over-year to $37.4 million; the TTM value through Dec 2025 reached $37.4 million, down 55.62%, while the annual FY2025 figure was $32.3 million, 13.25% down from the prior year.
  • Cash & Equivalents reached $37.4 million in Q4 2025 per ENTA's latest filing, up from $32.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $99.1 million in Q4 2021 to a low of $4.6 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $54.1 million, with a median of $44.4 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: plummeted 95.39% in 2021, then surged 516.54% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $99.1 million in 2021, then tumbled by 57.38% to $42.2 million in 2022, then fell by 5.42% to $39.9 million in 2023, then surged by 111.23% to $84.3 million in 2024, then crashed by 55.62% to $37.4 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Cash & Equivalents are $37.4 million (Q4 2025), $32.3 million (Q3 2025), and $44.8 million (Q2 2025).